Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

Laith Aburaddad, Lorenzo Sabatelli, Jerusha T. Achterberg, Jonathan D. Sugimoto, Ira M. Longini, Christopher Dye, M. Elizabeth Halloran

Research output: Contribution to journalArticle

243 Citations (Scopus)

Abstract

The Bill and Melinda Gates Foundation supports an ambitious portfolio of novel vaccines, drug regimens, and diagnostic tools for tuberculosis (TB). We elicited the expected efficacies and improvements of the novel interventions in discussions with the foundations managing their development. Using an age-structured mathematical model of TB, we explored the potential benefits of novel interventions under development and those not yet in the portfolio, focusing on the WHO Southeast Asia region. Neonatal vaccination with the portfolio vaccine decreases TB incidence by 39% to 52% by 2050. Drug regimens that shorten treatment duration and are efficacious against drug-resistant strains reduce incidence by 10-27%. New diagnostics reduce incidence by 13-42%. A triple combination of a portfolio vaccine, drug regimen, and diagnostics reduces incidence by 71%. A short mass vaccination catch-up campaign, not yet in the portfolio, to augment the triple combination, accelerates the decrease, preventing >30% more cases by 2050 than just the triple combination. New vaccines and drug regimens targeted at the vast reservoir of latently infected people, not in the portfolio, would reduce incidence by 37% and 82%, respectively. The combination of preventive latent therapy and a 2-month drug treatment regimen reduces incidence by 94%. Novel technologies in the pipeline would achieve substantial reductions in TB incidence, but not the Stop TB Partnership target for elimination. Elimination will require new delivery strategies, such as mass vaccination campaigns, and new products targeted at latently infected people.

Original languageEnglish
Pages (from-to)13980-13985
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume106
Issue number33
DOIs
Publication statusPublished - 18 Aug 2009
Externally publishedYes

Fingerprint

Tuberculosis Vaccines
Incidence
Pharmaceutical Preparations
Tuberculosis
Mass Vaccination
Vaccines
Immunization Programs
Southeastern Asia
Vaccination
Theoretical Models
Therapeutics
Technology

Keywords

  • Latent infection
  • Latent therapy
  • Novel interventions
  • Transmission model

ASJC Scopus subject areas

  • General

Cite this

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. / Aburaddad, Laith; Sabatelli, Lorenzo; Achterberg, Jerusha T.; Sugimoto, Jonathan D.; Longini, Ira M.; Dye, Christopher; Halloran, M. Elizabeth.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 33, 18.08.2009, p. 13980-13985.

Research output: Contribution to journalArticle

Aburaddad, Laith ; Sabatelli, Lorenzo ; Achterberg, Jerusha T. ; Sugimoto, Jonathan D. ; Longini, Ira M. ; Dye, Christopher ; Halloran, M. Elizabeth. / Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. In: Proceedings of the National Academy of Sciences of the United States of America. 2009 ; Vol. 106, No. 33. pp. 13980-13985.
@article{426abbec8ff64c858c531ac562163fff,
title = "Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics",
abstract = "The Bill and Melinda Gates Foundation supports an ambitious portfolio of novel vaccines, drug regimens, and diagnostic tools for tuberculosis (TB). We elicited the expected efficacies and improvements of the novel interventions in discussions with the foundations managing their development. Using an age-structured mathematical model of TB, we explored the potential benefits of novel interventions under development and those not yet in the portfolio, focusing on the WHO Southeast Asia region. Neonatal vaccination with the portfolio vaccine decreases TB incidence by 39{\%} to 52{\%} by 2050. Drug regimens that shorten treatment duration and are efficacious against drug-resistant strains reduce incidence by 10-27{\%}. New diagnostics reduce incidence by 13-42{\%}. A triple combination of a portfolio vaccine, drug regimen, and diagnostics reduces incidence by 71{\%}. A short mass vaccination catch-up campaign, not yet in the portfolio, to augment the triple combination, accelerates the decrease, preventing >30{\%} more cases by 2050 than just the triple combination. New vaccines and drug regimens targeted at the vast reservoir of latently infected people, not in the portfolio, would reduce incidence by 37{\%} and 82{\%}, respectively. The combination of preventive latent therapy and a 2-month drug treatment regimen reduces incidence by 94{\%}. Novel technologies in the pipeline would achieve substantial reductions in TB incidence, but not the Stop TB Partnership target for elimination. Elimination will require new delivery strategies, such as mass vaccination campaigns, and new products targeted at latently infected people.",
keywords = "Latent infection, Latent therapy, Novel interventions, Transmission model",
author = "Laith Aburaddad and Lorenzo Sabatelli and Achterberg, {Jerusha T.} and Sugimoto, {Jonathan D.} and Longini, {Ira M.} and Christopher Dye and Halloran, {M. Elizabeth}",
year = "2009",
month = "8",
day = "18",
doi = "10.1073/pnas.0901720106",
language = "English",
volume = "106",
pages = "13980--13985",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "33",

}

TY - JOUR

T1 - Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

AU - Aburaddad, Laith

AU - Sabatelli, Lorenzo

AU - Achterberg, Jerusha T.

AU - Sugimoto, Jonathan D.

AU - Longini, Ira M.

AU - Dye, Christopher

AU - Halloran, M. Elizabeth

PY - 2009/8/18

Y1 - 2009/8/18

N2 - The Bill and Melinda Gates Foundation supports an ambitious portfolio of novel vaccines, drug regimens, and diagnostic tools for tuberculosis (TB). We elicited the expected efficacies and improvements of the novel interventions in discussions with the foundations managing their development. Using an age-structured mathematical model of TB, we explored the potential benefits of novel interventions under development and those not yet in the portfolio, focusing on the WHO Southeast Asia region. Neonatal vaccination with the portfolio vaccine decreases TB incidence by 39% to 52% by 2050. Drug regimens that shorten treatment duration and are efficacious against drug-resistant strains reduce incidence by 10-27%. New diagnostics reduce incidence by 13-42%. A triple combination of a portfolio vaccine, drug regimen, and diagnostics reduces incidence by 71%. A short mass vaccination catch-up campaign, not yet in the portfolio, to augment the triple combination, accelerates the decrease, preventing >30% more cases by 2050 than just the triple combination. New vaccines and drug regimens targeted at the vast reservoir of latently infected people, not in the portfolio, would reduce incidence by 37% and 82%, respectively. The combination of preventive latent therapy and a 2-month drug treatment regimen reduces incidence by 94%. Novel technologies in the pipeline would achieve substantial reductions in TB incidence, but not the Stop TB Partnership target for elimination. Elimination will require new delivery strategies, such as mass vaccination campaigns, and new products targeted at latently infected people.

AB - The Bill and Melinda Gates Foundation supports an ambitious portfolio of novel vaccines, drug regimens, and diagnostic tools for tuberculosis (TB). We elicited the expected efficacies and improvements of the novel interventions in discussions with the foundations managing their development. Using an age-structured mathematical model of TB, we explored the potential benefits of novel interventions under development and those not yet in the portfolio, focusing on the WHO Southeast Asia region. Neonatal vaccination with the portfolio vaccine decreases TB incidence by 39% to 52% by 2050. Drug regimens that shorten treatment duration and are efficacious against drug-resistant strains reduce incidence by 10-27%. New diagnostics reduce incidence by 13-42%. A triple combination of a portfolio vaccine, drug regimen, and diagnostics reduces incidence by 71%. A short mass vaccination catch-up campaign, not yet in the portfolio, to augment the triple combination, accelerates the decrease, preventing >30% more cases by 2050 than just the triple combination. New vaccines and drug regimens targeted at the vast reservoir of latently infected people, not in the portfolio, would reduce incidence by 37% and 82%, respectively. The combination of preventive latent therapy and a 2-month drug treatment regimen reduces incidence by 94%. Novel technologies in the pipeline would achieve substantial reductions in TB incidence, but not the Stop TB Partnership target for elimination. Elimination will require new delivery strategies, such as mass vaccination campaigns, and new products targeted at latently infected people.

KW - Latent infection

KW - Latent therapy

KW - Novel interventions

KW - Transmission model

UR - http://www.scopus.com/inward/record.url?scp=69549083228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549083228&partnerID=8YFLogxK

U2 - 10.1073/pnas.0901720106

DO - 10.1073/pnas.0901720106

M3 - Article

VL - 106

SP - 13980

EP - 13985

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 33

ER -